Group 1 - The stock price of Enwei Pharmaceutical (301331) closed at 32.37 yuan on November 14, 2025, down 0.77%, with a turnover rate of 2.32% and a trading volume of 23,800 shares, amounting to a transaction value of 77.6852 million yuan [1] - On November 14, the net inflow of main funds was 1.1213 million yuan, indicating a positive short-term attitude from major investors towards the stock [3] - Enwei Pharmaceutical participated in the establishment of a venture capital fund with a contribution of 20 million yuan, accounting for 9.9502% of the total fund size of 201 million yuan, focusing on early and growth-stage companies in the medical and technology sectors [1][3] Group 2 - The company completed the second vesting period of its 2023 restricted stock incentive plan, with 760,200 shares vested, representing 0.7388% of the total share capital [1][3] - The vesting price for the shares was set at 13.48 yuan per share, and the company achieved a performance target with a 17.43% increase in revenue for 2024 compared to 2022, resulting in an 80% vesting ratio [1]
股市必读：恩威医药（301331）11月14日主力资金净流入112.13万元